Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

A statistically significantly lower risk of dementia or cognitive impairment was observed with GLP-1RAs, though not with SGLT2is or pioglitazone.

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Karen Coe, 59, who has type 2 diabetes, says she was prescribed a GLP-1 medication to help her lose weight and get her ...

Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to ...

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

A study from the Arkansas Agricultural Experiment Station finds that GLP-1 medications, such as Ozempic and Wegovy, are ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

investigating the impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on the incidence of atrial fibrillation ...

or glucagon-like peptide-1, receptor agonists. The drugs were first used to treat diabetes but drugmakers have introduced newer brands such as Wegovy and Zepbound approved for people with obesity.